Real‐life effectiveness and short‐term (16‐week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre study

We read with great interest the multicenter and retrospective study of Fougerosse et al1 that investigated real-life effectiveness and tolerance of guselkumab at week 16 in the treatment of cutaneous psoriasis. In the same manner, we conducted the first multicenter study in Belgium aiming to investigate real-life effectiveness and tolerance of guselkumab at week 16 in the treatment of cutaneous psoriasis. Guselkumab is the first selective interleukin (IL)-23 p19 inhibitor (Tremfya®, Janssen Biotech, Inc., Horsham, PA, USA) marketed and reimbursed in Belgium.